Intelligence
Pricing

Healthcare

Microbix Exhibiting New Innovations at ESCMID Global 2026

Author:
FAQSIR News Desk
Last Updated:
Reading Time
2 min

Microbix Biosystems Inc., a Canadian innovator in life sciences, is preparing to exhibit its latest advancements at ESCMID Global 2026, scheduled for April 17-21 in Munich, Germany. The company will feature its quality assessment products, specifically the QAP™ system, designed to enhance the reliability and accuracy of molecular assays that identify RNA-based viruses, such as those detected through RT-PCR tests.

#Presenting Key Innovations

During the congress organized by the European Society of Clinical Microbiology and Infectious Diseases, Microbix will not only showcase its QAP innovations but also provide insights into its QUANTDx™ quantified reference materials. These tools are essential for developing various diagnostic assays related to syndromic conditions, viral variants, and antimicrobial resistance, among other areas.

Microbix will also present a poster titled "Development of non-infectious phage-encapsulated RNA control to support PCR assay development during outbreaks of viral pathogens." This research outlines the successful creation of a stable, replicable control mimicking the Hepatitis C virus, providing a safer option for laboratories that need reliable quality management solutions for RNA-based tests.

#Importance of ESCMID Global 2026

ESCMID Global serves as a crucial platform for professionals in infectious disease and clinical microbiology to congregate and exchange innovative ideas. The event consists of multiple sessions, including keynote speeches, workshops, and poster presentations, making it a significant opportunity for Microbix to engage with potential collaborators and expand their reach in the diagnostics market.

Microbix's focus on meeting the quality management system (QMS) needs for laboratory assays positions the company as a valuable partner in the global diagnostics industry, particularly as public health challenges continue to evolve.

#About Microbix Biosystems Inc.

Microbix Biosystems, headquartered in Mississauga, Ontario, is recognized for its production of proprietary biological products integral to healthcare. With numerous regulatory credentials, including ISO certifications and FDA registration, the company supplies critical components to the diagnostics field.

The ongoing innovations in their product lines, particularly the QAP™ and QUANTDx™, underscore Microbix’s commitment to improving public health outcomes through reliable diagnostics.

#Key Takeaways

  • Microbix will showcase its QAP™ and QUANTDx™ products at ESCMID Global 2026.
  • The new QAP™ products aim to enhance quality management of RNA-based molecular assays.
  • A poster on a novel RNA control supporting PCR assay development will be presented.
  • ESCMID Global is a major gathering for experts in infectious diseases and diagnostics.
  • Microbix continues to position itself as a leader in quality assurance solutions in the diagnostics industry.

Original source: Read original article

Frequently Asked Questions

Microbix will showcase its novel quality assessment product (QAP™) for managing molecular assays that detect RNA-based viruses. Additionally, the presentation includes QUANTDx™ reference materials aimed at supporting various assay developments, demonstrating the company's commitment to advancing diagnostic accuracy.
ESCMID Global represents a premier gathering for experts in infectious diseases and microbiology, providing Microbix a vital platform to highlight its innovative products. This visibility can strengthen partnerships and expand market opportunities within the vital diagnostics sector.
Microbix's QAP™ products are designed for a broad range of RNA-based viruses, enhancing quality management in laboratories. Their application could lead to improved diagnostic results for serious health concerns, ensuring safety and reliability in clinical settings.
Microbix supplies essential biological products, including antigens and reference materials, crucial for the diagnostics market. With its focus on quality and innovation, the company positions itself as a significant player supporting clinical laboratories and diagnostics companies worldwide.
Microbix's commitment to innovation and expanding its product offerings at events like ESCMID Global indicates a robust growth strategy. The ongoing development of new quality assessment tools aligns with increasing global demand for reliable diagnostic solutions, potentially enhancing investor confidence.
Microbix's products, including its QAPs™ and QUANTDx™, play a crucial role in ensuring the accuracy of diagnostic tests for various infectious diseases. Their focus on high-quality control measures supports public health outcomes by enabling faster and more reliable diagnostics.
Microbix is ISO certified and registered with regulatory bodies like the U.S. FDA and Health Canada, ensuring that its products meet stringent quality and safety standards. This compliance underscores the company’s commitment to delivering reliable and effective solutions in the diagnostics sector.
The poster presentation on the development of a non-infectious RNA control reflects Microbix's innovative approach to challenges in assay development. Highlighting research that can enhance laboratory practices signals to investors the company’s focus on leading advancements in diagnostics.